Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y285

UPID:
SYFA_HUMAN

ALTERNATIVE NAMES:
CML33; Phenylalanyl-tRNA synthetase alpha subunit

ALTERNATIVE UPACC:
Q9Y285; B4E363; Q9NSD8; Q9Y4W8

BACKGROUND:
Phenylalanine--tRNA ligase alpha subunit, known alternatively as CML33 and Phenylalanyl-tRNA synthetase alpha subunit, is integral to the translation process, attaching phenylalanine to its tRNA. This action is pivotal for the synthesis of proteins, which are essential for cellular function and organismal development.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Phenylalanine--tRNA ligase alpha subunit could open doors to potential therapeutic strategies for Rajab interstitial lung disease with brain calcifications 2, characterized by severe lung and brain pathologies, underscoring the protein's significance in disease mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.